.3
Paris, January 22nd, 2018
Dear Bioverativ Employees,
Today, Bioverativ and Sanofi announced an agreement that will bring Bioverativ into the Sanofi family. As the Chief Executive Officer of Sanofi, I’d like to introduce myself and share with you why we feel so strongly that Sanofi and Bioverativ are better together.
First and foremost, we are excited to bring the entrepreneurial spirit and steadfast patient commitment of Bioverativ employees to Sanofi. We share a passion for patient care and, together, we will continue to bring innovative, impactful medicines to patients. Sanofi is committed to supporting Bioverativ’s humanitarian aid program in hemophilia, which we know has made a life-changing impact for people with hemophilia in developing countries.
I want to express how we at Sanofi admire Bioverativ’s leadership in the growing hemophilia market. From your history as part of Biogen when you launched ELOCTATE® and ALPROLIX®, to the successful spin-off last year, followed by strong growth and a significant acquisition, Bioverativ has accomplished a lot in a short period of time. Together, we look forward to continuing your track record of success and creating a platform for expansion in hemophilia and other rare blood disorders.
Sanofi is a global, diversified healthcare company made up of approximately 100,000 people across all continents. We are pleased to welcome you to join us in transforming healthcare.
In joining us, you will become part of an organization that shares a strong focus on patients and innovative rare disease drug discovery and development. We have complementary strengths and look forward to learning from each other for the advancement of medicine worldwide. In particular, Sanofi’s global commercial presence and established footprint in key Emerging Markets can be used to help Bioverativ fully capitalize on growth opportunities for current and future products. We also look forward to applying Sanofi’s specialty care expertise and ability to rapidly design and execute multiple clinical programs to help bring Bioverativ’s pipeline to patients in need faster.
Today marks the first step in this process. Until the deal is completed, which is expected to occur within three months, subject to conditions, such as antitrust clearance and other customary requirements, Bioverativ will continue to operate as a separate company. You have created a culture that cares about patients and science and you have delivered impressive results. Maintaining this momentum is critical as we move into this next chapter together. Upon closing, I will personally oversee Bioverativ to ensure the smoothest possible transition for the teams.
